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INTRODUCTION
Treosulfan (L-threitol 1,4-bismethanesulphonate, Ovastat; Figure
1), synthesized more than 30 years ago (Feit, 1961, 1964),
possesses a broad spectrum of anti-tumour activity (White, 1962).
The clinical experience with the drug is, however, limited largely
to oral and intravenous treatment of patients with advanced
ovarian cancer (Lundrall, 1976; Fennelly, 1977; Breitbach et al,
1994), although toxicological evaluation and clinical experience
revealed the lack of significant non-haematological toxicity, which
suggests treosulfan as a promising candidate for high-dose
chemotherapy with autologous stem cell reinfusion.
Although treosulfan shows some structural similarity to the
alkylating agent busulphan, its mechanism of alkylation is distinct.
Unlike busulphan, which alkylates as a primary methane-
sulphonate, treosulfan is a prodrug for epoxy compounds and
converts non-enzymatically to L-diepoxybutane via the corre-
sponding monoepoxide under physiological conditions (Feit et al,
1970; Figure 1). The cytotoxicity of treosulfan is assumed to be
due to alkylation of DNA and the formation of DNA interstrand
cross-links, although this has not been proven. In the present study,
the alkylation and cross-linking of DNA is confirmed both in cell-
free systems and in intact cells. In addition, the cytotoxicity and
cross-linking is confirmed to be due to the conversion of treo-
sulfan to the epoxide species.
MATERIALS AND METHODS
Cell culture and cytotoxicity studies
The human chronic myelogenous leukaemic cell line K562 as a
suspension culture was grown at 37°C in an atmosphere of 95%
air/5% carbon dioxide in RPMI-1640 containing 10% heat-inacti-
vated fetal bovine serum and 2 mM glutamine. Cytotoxicity was
assessed in K562 cells using the MTT assay (Carmichael et al,
1987). Cells were cultured in 96-well plates and grown for 4 days
before staining with MTT.
Drug treatment
Treosulfan was obtained as the crystalline preparation for clinical
use (Ovastat) from Medac, Hamburg, Germany. Stock solutions
(20 mM) of treosulfan were prepared immediately before use in
either water or sterile medium. Where appropriate, conversion of
treosulfan to the corresponding epoxides was achieved in solution
by the addition of sodium hydroxide (Figure 1). This transforma-
tion was accomplished by addition of 1.33 mol sodium hydroxide
per mol of treosulfan, resulting in a mixture of the corresponding
monoepoxide and L-diepoxybutane in approximately equal
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Figure 1 Structure of treosulfan and its spontaneous pH-dependent
activation into the monoepoxide (2S,3S)-1,2-epoxy-3,4 butanediol 4-
methanesulphonate and the diepoxide, L-diepoxybutaneAlkylation and cross-linking by treosulfan 265
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amounts (Feit et al, 1970). The alkaline transformation of aqueous
solutions of treosulfan was confirmed by high-performance
liquid chromatographic (HPLC) analysis (PW Feit, personal
communication).
DNA interstrand cross-linking in plasmid DNA
BamHI linearized and dephosphorylated pBR322 DNA was 5¢-end
labelled with T4 polynucleotide kinase and [g-32P]ATP (5000 Ci
mmol–1, Amersham), and ~10 ng of labelled DNA was used for
each experimental point. Reactions with drug were performed in
25 mM triethanolamine, 1 mM EDTA (pH 7.2) at 37°C and termi-
nated by the addition of an equal volume of stop solution (0.6 M
sodium acetate, 20 mM EDTA, 100 mg ml–1 tRNA). The samples
were precipitated, denatured and electrophoresed exactly as
described previously (Hartley et al, 1991).
Taq polymerase stop assay
The procedure was an application of the method of Ponti et al
(1991a). Before drug/DNA incubation, plasmid pBR322 DNA
was linearized with HindIII to provide a stop for the Taq down-
stream of the primer. The oligodeoxynucleotide primers were 5¢-
end labelled before amplification using T4 polynucleotide kinase
and [g-32P]ATP (5000 Ci mmol–1, Amersham). The labelled
primers were purified by elution through BioRad BioSpin
columns. The synthetic primer used for amplification of a 330-bp
region was 5¢-GTCGCCATGATCGGCGTAGTC. Linear amplifi-
cation of DNA was carried out in a total volume of 100 ml
containing 0.5 mg template DNA, 5 pmol labelled primer, 125 mM
each dNTP, 1 U Taq polymerase, 20 mM diammonium sulphate, 75
mM tris-HCl, pH 9, 0.01% Tween, 2.5 mM magnesium chloride
and 0.05% gelatin. After an initial denaturation at 94°C for 1 min,
the cycling conditions were as follows: 94°C for 1 min, 60°C for 1
min, and 72°C for 1 min, for a total of 30 cycles. Samples were
precipitated and electrophoresed as described previously (Ponti et
al, 1991a).
Alkaline elution analysis
Analysis of DNA interstrand cross-link formation in K562 cells
was carried out using alkaline elution as described by Kohn et al
(1981).
RESULTS
After a 1-h exposure of human leukaemic K562 cells to treosulfan,
there is little effect on cell survival at doses up to 1 mM. In
contrast, treatment for 1 h with treosulfan that has been pre-incu-
bated with sodium hydroxide to convert it to the corresponding
monoepoxide and L-diepoxybutane (Figure 1) showed significant
cell killing, with an IC50 (dose of drug producing 50% loss in cell
survival) of 115 mM. If, however, treosulfan is administered
continuously to the cells during the cell survival assay, cell killing
is observed with an IC50 of 75 mM. Under these conditions, the
epoxide mixture was again more cytotoxic with an IC50 value of
20 mM, but the difference between the parent drug and the
pretransformed epoxides was much less.
The ability of treosulfan to produce DNA interstrand cross-links
was tested using a sensitive agarose gel-based plasmid DNA assay
(Figure 2). Treosulfan was able to produce cross-links after a 4-h
exposure, but 10 mM drug was required to produce 8.9%
crosslinking (Figure 2B). With a 24-h exposure to treosulfan
(Figure 2D), cross-linking at 10 mM had increased to 62.2%, with
11.6% cross-linking at 1 mM. In contrast, significant cross-linking
was observed with the preformed epoxides at 4 h (Figure 2A),
with 29.7% cross-linking at 10 mM increasing to 90.7% with a 24-
h exposure (Figure 2C).
The sequence specificity of covalent binding to DNA by treo-
sulfan was examined using a Taq polymerase stop assay (Figure
3). After a 4-h exposure to treosulfan, significant blocks to the
polymerase were only observed at 10 mM (lane E). With the
preformed epoxides, a similar level of blockage was observed with
1m M (lane B), and at 10 mM (lane C) extensive evidence of cova-
lent binding was observed. Examination of the sites of blockage
revealed alkylation at guanine bases with a preference for runs of
contiguous guanines, as has been observed previously with alkyl-
ating agents such as nitrogen mustards. The pattern of damage was
different to cisplatin (lane F), which produced blocks primarily at
GG and AG sites (Ponti et al, 1991a). Alkylation by the epoxides
was confirmed as guanine-N7 alkylation using a piperidine
cleavage-based sequencing assay (data not shown).
DNA cross-linking in K562 cells was investigated using alka-
line elution. After a 1-h exposure of cells to treosulfan followed by
a 4-h incubation in drug-free medium, cross-links were just
detectable at 10 mM treosulfan with increased levels at 100 mM
(data not shown). A higher level of cross-links was observed under
identical conditions when the cells were treated with 10 mM of the
preformed epoxides, which increased at 100 mM. In unirradiated
samples, no evidence of drug-induced single-strand breakage was
observed with either agent (data not shown). When cells were
treated with treosulfan continuously, cross-links formed slowly
and were still increasing at 15 h, consistent with the slow non-
enzymatic conversion of treosulfan to the diepoxide.
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Figure 2 DNA interstrand cross-linking by treosulfan in plasmid DNA. Drug
treatment was either for 4 h (A, B) or 24 h (C, D). Treosulfan was either
administered directly (B, D) or after conversion to the corresponding
monoepoxide and L-diepoxybutane (A, C). The dose of drug was 0.01 mM
(lane 1), 0.1 mM (lane 2), 1 mM (lane 3), or 10 mM (lane 4). C1 is control, non-
denatured DNA and C2 is control, denatured DNA. Samples in lanes 1–4
were denatured before gel loading; ds and ss are double-stranded and
single-stranded DNA respectively266 JA Hartley et al
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DISCUSSION
Alkylation and interstrand cross-linking of DNA by treosulfan has
been demonstrated in cell-free systems and in intact cells.
Conversion of treosulfan to epoxide species (Figure 1) is required
for alkylation and cross-linking to occur and resultant cytotoxicity.
Although structurally similar to busulphan, its mechanism of
alkylation is, therefore, distinct. However, the ultimate sites of
alkylation on DNA are identical to those previously described for
busulphan (Ponti et al, 1991b). The initial alkylation event
produced by treosulfan on DNA is primarily at the guanine N-7
position with the preference for contiguous runs of guanines. This
has previously been shown for other bifunctional agents such as
nitrogen mustards (Mattes et al, 1986; Hartley, 1993) and busul-
phan (Ponti et al, 1991b). The four carbon cross-links produced by
treosulfan should span the same distance on DNA as busulphan
(6.0 Å), which is unlikely to be between two guanine N-7 positions
because the shortest distance between N7 atoms on opposite
strands is approximately 8.0 Å in B-form DNA. The rate of cross-
link formation by busulphan is slow and still increasing at 24h
(Ponti et al, 1991b). With treosulfan, cross-link formation in naked
DNA and cells is also slow, but this reflects the slow conversion of
treosulfan to the active epoxide species.
Alkylation of DNA requires conversion of treosulfan to the
monoepoxide and cross-linking can only occur via a diepoxide
species. In vitro, cross-linking is clearly at sub-millimolar concen-
trations of drug. In patients, peak plasma levels of treosulfan
reach ~2mMafter conventional doses of 8–10gm–2 over a 0.5-h
infusion (Hilger et al, 1998). Levels of ~4mMare achieved after
high-dose therapy with stem cell support at a dose of 32.5g m–2
given as a 2-h infusion (Scheulen et al, 1997). Until now, there are
no published reports concerning the levels of the corresponding
epoxide species in the plasma of patients undergoing treosulfan
therapy. Possibly, the lipophilicity of the epoxides is resulting in a
rapid disappearance from the first compartment. A bolus injection
of L-diepoxybutane to dogs led to the rapid disappearance of the
compound within minutes even though the chemical stability of L-
diepoxybutane in plasma is high (T1/2 = 7h ex vivo) (PW Feit,
personal communication).
Since its initial synthesis over 30 years ago, the mechanism of
action of treosulfan has been assumed to be as a bifunctional alkyl-
ating agent after conversion non-enzymatically to the epoxide
species. The present study confirms this mechanism.
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Figure 3Sequence specificity of alkylation of plasmid DNA by treosulfan.
Lane A, control, undamaged plasmid; lane B, epoxide mixture, 1mM; lane C,
epoxide mixture, 10mM; lane D, treosulfan, 1mM; lane E, treosulfan, 10mM;
lane F, cisplatin, 50mM. Drug reactions were for 4h at 37°C. Numbers refer
to the base sequence position in pBR322 DNA and arrows indicate the
position of runs of two or more contiguous guanine bases